Bladder cancer tumor cells

Bladder cancer tumor cells, primarily consisting of urothelial carcinoma cells, are the malignant cells that originate in the urinary bladder lining (NIH National Cancer Institute, 2023). These cells are characterized by significant genetic heterogeneity, often harboring mutations in genes such as FGFR3, TP53, and RB1, which drive uncontrolled growth and resistance to programmed cell death (Nature Reviews Disease Primers, 2017). While the term refers to a cellular population rather than a specific molecular target, these cells express various receptors and antigens that are exploited for therapeutic purposes. For example, antibody-drug conjugates like enfortumab vedotin target Nectin-4 on the cell surface to deliver potent cytotoxins, while checkpoint inhibitors like pembrolizumab disrupt the PD-1/PD-L1 interaction to enhance the body's immune response against the tumor (Journal of Clinical Oncology, 2021). In early-stage disease, intravesical administration of Bacillus Calmette-Guérin (BCG) is used to stimulate a localized inflammatory response that eliminates these malignant cells (Urologic Oncology, 2020). Understanding the molecular profile of these cells is essential for the application of targeted therapies and the identification of predictive biomarkers for treatment efficacy.

Other names

Urothelial carcinoma cellsTransitional cell carcinoma cellsBladder neoplasm cellsMalignant bladder cells

Therapeutic strategies targeting bladder cancer tumor cells include DNA damage via alkylating agents, inhibition of the PD-1/PD-L1 immune checkpoint axis, selective inhibition of fibroblast growth factor receptors (FGFR), and delivery of cytotoxic payloads via antibody-drug conjugates (ADCs) targeting surface antigens like Nectin-4 or TROP2.